No connection

Search Results

ABBV vs LFST

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
LFST
LifeStance Health Group, Inc.
NEUTRAL
Price
$6.40
Market Cap
$2.45B
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
ABBV
163.63
LFST
320.0
Forward P/E
ABBV
15.42
LFST
16.74
P/B Ratio
ABBV
-146.66
LFST
1.63
P/S Ratio
ABBV
6.5
LFST
1.72
EV/EBITDA
ABBV
15.27
LFST
34.04

Profitability

Gross Margin
ABBV
71.46%
LFST
32.37%
Operating Margin
ABBV
35.5%
LFST
4.74%
Profit Margin
ABBV
4.0%
LFST
0.68%
ROE
ABBV
137.96%
LFST
0.65%
ROA
ABBV
9.59%
LFST
0.73%

Growth

Revenue Growth
ABBV
9.1%
LFST
17.4%
Earnings Growth
ABBV
-88.7%
LFST
--

Financial Health

Debt/Equity
ABBV
--
LFST
0.31
Current Ratio
ABBV
0.72
LFST
1.65
Quick Ratio
ABBV
0.47
LFST
1.38

Dividends

Dividend Yield
ABBV
3.05%
LFST
--
Payout Ratio
ABBV
490.15%
LFST
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
LFST NEUTRAL

LFST presents a stable but precarious financial profile with a Piotroski F-Score of 4/9 and no Altman Z-Score provided for bankruptcy risk assessment. While the company has successfully transitioned toward profitability with a promising forward P/E of 16.74, it trades at a massive premium compared to its Graham Number ($1.33) and Intrinsic Value ($0.14). Strong revenue growth of 17.4% is offset by razor-thin profit margins (0.68%) and aggressive insider selling totaling $32.51M. The stock is currently a speculative play on earnings expansion rather than a value-driven investment.

Strengths
Low Debt/Equity ratio of 0.31 indicating manageable leverage
Consistent revenue growth of 17.4% YoY and Q/Q
Successful transition from historical losses to positive EPS
Risks
Extreme trailing P/E ratio of 320.00
Heavy insider selling totaling $32.51M in the last 6 months
Razor-thin net profit margins of 0.68%

Compare Another Pair

ABBV vs LFST: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and LifeStance Health Group, Inc. (LFST) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile